NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Jun 29, 2020

EL SEGUNDO, Calif — Jun. 29, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock (4,811,500 shares at a price to the public of $9.50 per share and 3,710,000 shares at a price of $12.12 per share to NantKwest’s chairman, chief executive officer and principal stockholder, Dr. Patrick Soon-Shiong), which includes 1,111,500 shares sold upon full exercise of the underwriters’ option to purchase additional shares at a public offering price of $9.50 per share, less the underwriting discounts and commissions. All of the shares were offered by NantKwest. Including the option exercise, the aggregate gross proceeds of the offering were approximately $90.7 million, before deducting the underwriting discounts and commissions and other offering expenses.

Piper Sandler & Co. acted as the sole book-running manager for the offering. LifeSci Capital acted as co-manager for the offering.

A shelf registration statement on Form S-3 (File No. 333-233434) related to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (the “SEC”) on August 23, 2019 and declared effective by the SEC on September 3, 2019. The offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A final prospectus supplement and accompanying prospectus related to the offering were filed with the SEC on June 25, 2020 and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus related to the offering may also be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at (800) 747-3924 or via email at prospectus@psc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NantKwest

NantKwest (NASDAQ: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and virally-induced infectious diseases.

Corporate Contact:
Sarah Singleton
1 (844) 696-5235, option 5
Sarah.Singleton@nantkwest.com

Source: NantKwest, Inc.

Contact us at

844-696-5235

How Can ImmunityBio Help You?

Solutions for Patients

Many therapies for treating cancer and infectious diseases severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

Natural killer cell-based immunotherapies are key to future cancer treatments. Our investigational NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.

Solutions for Research Scientists

Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.